DK2938332T3 - Depot-lipidprækoncentrat af gnrh-analoger og farmaceutisk sammensætning dermed - Google Patents
Depot-lipidprækoncentrat af gnrh-analoger og farmaceutisk sammensætning dermed Download PDFInfo
- Publication number
- DK2938332T3 DK2938332T3 DK13867921.2T DK13867921T DK2938332T3 DK 2938332 T3 DK2938332 T3 DK 2938332T3 DK 13867921 T DK13867921 T DK 13867921T DK 2938332 T3 DK2938332 T3 DK 2938332T3
- Authority
- DK
- Denmark
- Prior art keywords
- sorbitan
- pharmaceutical composition
- weight
- group
- amount
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 71
- 238000002360 preparation method Methods 0.000 title description 4
- 101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 title 1
- 102100024028 Progonadoliberin-1 Human genes 0.000 title 1
- 239000004973 liquid crystal related substance Substances 0.000 claims abstract description 54
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 claims abstract description 42
- 239000013543 active substance Substances 0.000 claims abstract description 36
- 150000003904 phospholipids Chemical class 0.000 claims abstract description 22
- -1 sorbitan unsaturated fatty acid ester Chemical class 0.000 claims abstract description 21
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 claims abstract description 19
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 claims abstract description 17
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 claims abstract description 17
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims abstract description 14
- 150000002632 lipids Chemical class 0.000 claims abstract description 12
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 11
- 239000007791 liquid phase Substances 0.000 claims abstract description 10
- 230000002209 hydrophobic effect Effects 0.000 claims abstract description 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 9
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229960004338 leuprorelin Drugs 0.000 claims description 30
- 108010000817 Leuprolide Proteins 0.000 claims description 29
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 claims description 28
- 239000007788 liquid Substances 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 12
- 108010069236 Goserelin Proteins 0.000 claims description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 8
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 claims description 7
- 229960002913 goserelin Drugs 0.000 claims description 7
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 claims description 7
- MEUCPCLKGZSHTA-XYAYPHGZSA-N degarelix Chemical compound C([C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CC=1C=CC(NC(=O)[C@H]2NC(=O)NC(=O)C2)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(NC(N)=O)C=C1 MEUCPCLKGZSHTA-XYAYPHGZSA-N 0.000 claims description 6
- 108010052004 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide Proteins 0.000 claims description 5
- 229960002272 degarelix Drugs 0.000 claims description 5
- 239000003163 gonadal steroid hormone Substances 0.000 claims description 5
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical group FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 claims description 4
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims description 4
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 claims description 4
- 125000005907 alkyl ester group Chemical group 0.000 claims description 4
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 claims description 4
- 235000012000 cholesterol Nutrition 0.000 claims description 4
- 230000001419 dependent effect Effects 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 201000002859 sleep apnea Diseases 0.000 claims description 4
- 239000001593 sorbitan monooleate Substances 0.000 claims description 4
- 229940035049 sorbitan monooleate Drugs 0.000 claims description 4
- 235000011069 sorbitan monooleate Nutrition 0.000 claims description 4
- 229940042585 tocopherol acetate Drugs 0.000 claims description 4
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 claims description 3
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 claims description 3
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 201000009273 Endometriosis Diseases 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 206010046798 Uterine leiomyoma Diseases 0.000 claims description 3
- 239000002474 gonadorelin antagonist Substances 0.000 claims description 3
- 230000001456 gonadotroph Effects 0.000 claims description 3
- 229940121381 gonadotrophin releasing hormone (gnrh) antagonists Drugs 0.000 claims description 3
- 208000000509 infertility Diseases 0.000 claims description 3
- 230000036512 infertility Effects 0.000 claims description 3
- 231100000535 infertility Toxicity 0.000 claims description 3
- 201000010260 leiomyoma Diseases 0.000 claims description 3
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 3
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims description 3
- 208000006155 precocious puberty Diseases 0.000 claims description 3
- 229920006395 saturated elastomer Polymers 0.000 claims description 3
- 229960005078 sorbitan sesquioleate Drugs 0.000 claims description 3
- HJNZCKLMRAOTMA-BRBGIFQRSA-N (2s)-n-[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2r)-1-[[(2s)-1-[[(2s)-5-(diaminomethylideneamino)-1-[(2s)-2-(ethylcarbamoyl)pyrrolidin-1-yl]-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(2-methyl-1h-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(4-hydr Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=C(C)NC2=CC=CC=C12 HJNZCKLMRAOTMA-BRBGIFQRSA-N 0.000 claims description 2
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims description 2
- 108010037003 Buserelin Proteins 0.000 claims description 2
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims description 2
- GJKXGJCSJWBJEZ-XRSSZCMZSA-N Deslorelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CNC2=CC=CC=C12 GJKXGJCSJWBJEZ-XRSSZCMZSA-N 0.000 claims description 2
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims description 2
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims description 2
- 108010021717 Nafarelin Proteins 0.000 claims description 2
- 108010050144 Triptorelin Pamoate Proteins 0.000 claims description 2
- 229960002184 abarelix Drugs 0.000 claims description 2
- 108010023617 abarelix Proteins 0.000 claims description 2
- AIWRTTMUVOZGPW-HSPKUQOVSA-N abarelix Chemical compound C([C@@H](C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 AIWRTTMUVOZGPW-HSPKUQOVSA-N 0.000 claims description 2
- 229960002903 benzyl benzoate Drugs 0.000 claims description 2
- 229960002719 buserelin Drugs 0.000 claims description 2
- CUWODFFVMXJOKD-UVLQAERKSA-N buserelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 claims description 2
- 108700008462 cetrorelix Proteins 0.000 claims description 2
- 229960003230 cetrorelix Drugs 0.000 claims description 2
- SBNPWPIBESPSIF-MHWMIDJBSA-N cetrorelix Chemical compound C([C@@H](C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 SBNPWPIBESPSIF-MHWMIDJBSA-N 0.000 claims description 2
- 229940107161 cholesterol Drugs 0.000 claims description 2
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims description 2
- 235000017471 coenzyme Q10 Nutrition 0.000 claims description 2
- 239000003433 contraceptive agent Substances 0.000 claims description 2
- 108700025485 deslorelin Proteins 0.000 claims description 2
- 229960005408 deslorelin Drugs 0.000 claims description 2
- 108700032141 ganirelix Proteins 0.000 claims description 2
- 229960003794 ganirelix Drugs 0.000 claims description 2
- GJNXBNATEDXMAK-PFLSVRRQSA-N ganirelix Chemical compound C([C@@H](C(=O)N[C@H](CCCCN=C(NCC)NCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN=C(NCC)NCC)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 GJNXBNATEDXMAK-PFLSVRRQSA-N 0.000 claims description 2
- 108700020746 histrelin Proteins 0.000 claims description 2
- 229960002193 histrelin Drugs 0.000 claims description 2
- HHXHVIJIIXKSOE-QILQGKCVSA-N histrelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC(N=C1)=CN1CC1=CC=CC=C1 HHXHVIJIIXKSOE-QILQGKCVSA-N 0.000 claims description 2
- 108700025096 meterelin Proteins 0.000 claims description 2
- 229960002333 nafarelin Drugs 0.000 claims description 2
- RWHUEXWOYVBUCI-ITQXDASVSA-N nafarelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 RWHUEXWOYVBUCI-ITQXDASVSA-N 0.000 claims description 2
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims description 2
- 150000003905 phosphatidylinositols Chemical class 0.000 claims description 2
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 claims description 2
- 229940108325 retinyl palmitate Drugs 0.000 claims description 2
- 235000019172 retinyl palmitate Nutrition 0.000 claims description 2
- 239000011769 retinyl palmitate Substances 0.000 claims description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 2
- 229960004824 triptorelin Drugs 0.000 claims description 2
- VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 claims description 2
- 229940035936 ubiquinone Drugs 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 7
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 230000002254 contraceptive effect Effects 0.000 claims 1
- RZTAMFZIAATZDJ-UHFFFAOYSA-N felodipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-UHFFFAOYSA-N 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 238000013268 sustained release Methods 0.000 abstract description 37
- 239000012730 sustained-release form Substances 0.000 abstract description 37
- 239000012530 fluid Substances 0.000 abstract description 23
- 239000004848 polyfunctional curative Substances 0.000 abstract description 15
- 239000012141 concentrate Substances 0.000 abstract description 9
- 239000000203 mixture Substances 0.000 description 43
- RGLRXNKKBLIBQS-XNHQSDQCSA-N leuprolide acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 RGLRXNKKBLIBQS-XNHQSDQCSA-N 0.000 description 28
- 238000009472 formulation Methods 0.000 description 22
- 230000000052 comparative effect Effects 0.000 description 20
- 239000012071 phase Substances 0.000 description 19
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 19
- 239000003814 drug Substances 0.000 description 17
- 229940079593 drug Drugs 0.000 description 15
- 239000011859 microparticle Substances 0.000 description 14
- 238000002347 injection Methods 0.000 description 13
- 239000007924 injection Substances 0.000 description 13
- 230000015572 biosynthetic process Effects 0.000 description 11
- 238000001727 in vivo Methods 0.000 description 11
- 230000006399 behavior Effects 0.000 description 10
- 239000000243 solution Substances 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 7
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- 229940028334 follicle stimulating hormone Drugs 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- 238000000034 method Methods 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 4
- ZWGOKSXVMODEMQ-UHFFFAOYSA-N 3,7,11,15-tetramethylhexadecyl 2,3-dihydroxypropanoate Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)CCOC(=O)C(O)CO ZWGOKSXVMODEMQ-UHFFFAOYSA-N 0.000 description 4
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 4
- JPJYKWFFJCWMPK-KTKRTIGZSA-N [(z)-octadec-9-enyl] 2,3-dihydroxypropanoate Chemical compound CCCCCCCC\C=C/CCCCCCCCOC(=O)C(O)CO JPJYKWFFJCWMPK-KTKRTIGZSA-N 0.000 description 4
- 239000000556 agonist Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- UPWGQKDVAURUGE-UHFFFAOYSA-N glycerine monooleate Natural products CCCCCCCCC=CCCCCCCCC(=O)OC(CO)CO UPWGQKDVAURUGE-UHFFFAOYSA-N 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 238000010254 subcutaneous injection Methods 0.000 description 4
- 239000007929 subcutaneous injection Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 102000008238 LHRH Receptors Human genes 0.000 description 3
- 108010021290 LHRH Receptors Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000008827 biological function Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 125000005313 fatty acid group Chemical group 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 210000004368 gonadotroph Anatomy 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 108010078259 luprolide acetate gel depot Proteins 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 229940124531 pharmaceutical excipient Drugs 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- RBNPOMFGQQGHHO-UWTATZPHSA-N D-glyceric acid Chemical compound OC[C@@H](O)C(O)=O RBNPOMFGQQGHHO-UWTATZPHSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 108700012941 GNRH1 Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010020864 Hypertrichosis Diseases 0.000 description 2
- 206010062767 Hypophysitis Diseases 0.000 description 2
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 2
- 206010036618 Premenstrual syndrome Diseases 0.000 description 2
- 239000004820 Pressure-sensitive adhesive Substances 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 239000007857 degradation product Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 210000003722 extracellular fluid Anatomy 0.000 description 2
- 239000003889 eye drop Substances 0.000 description 2
- 229940012356 eye drops Drugs 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 210000003016 hypothalamus Anatomy 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 229940087857 lupron Drugs 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 210000003635 pituitary gland Anatomy 0.000 description 2
- 239000011505 plaster Substances 0.000 description 2
- 230000010287 polarization Effects 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 150000004671 saturated fatty acids Chemical group 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 208000010579 uterine corpus leiomyoma Diseases 0.000 description 2
- 201000007954 uterine fibroid Diseases 0.000 description 2
- RBNPOMFGQQGHHO-UHFFFAOYSA-N -2,3-Dihydroxypropanoic acid Natural products OCC(O)C(O)=O RBNPOMFGQQGHHO-UHFFFAOYSA-N 0.000 description 1
- AFSHUZFNMVJNKX-UHFFFAOYSA-N 1,2-di-(9Z-octadecenoyl)glycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(CO)OC(=O)CCCCCCCC=CCCCCCCCC AFSHUZFNMVJNKX-UHFFFAOYSA-N 0.000 description 1
- CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical group CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 description 1
- AFSHUZFNMVJNKX-LLWMBOQKSA-N 1,2-dioleoyl-sn-glycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](CO)OC(=O)CCCCCCC\C=C/CCCCCCCC AFSHUZFNMVJNKX-LLWMBOQKSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 108010086677 Gonadotropins Proteins 0.000 description 1
- 102000006771 Gonadotropins Human genes 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- AZLIXMDAMOHKAG-CVBJKYQLSA-N OCC(O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O Chemical compound OCC(O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O AZLIXMDAMOHKAG-CVBJKYQLSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- TTZKGYULRVDFJJ-GIVMLJSASA-N [(2r)-2-[(2s,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-[(z)-octadec-9-enoyl]oxyethyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1O TTZKGYULRVDFJJ-GIVMLJSASA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000001380 anti-conceptive effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000006059 cover glass Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 229960000377 degarelix acetate Drugs 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 150000001982 diacylglycerols Chemical class 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229940013317 fish oils Drugs 0.000 description 1
- 230000009969 flowable effect Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000008570 general process Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000002622 gonadotropin Substances 0.000 description 1
- 229960003690 goserelin acetate Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 239000000944 linseed oil Substances 0.000 description 1
- 235000021388 linseed oil Nutrition 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229940127554 medical product Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 235000021243 milk fat Nutrition 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- BLCLNMBMMGCOAS-UHFFFAOYSA-N n-[1-[[1-[[1-[[1-[[1-[[1-[[1-[2-[(carbamoylamino)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amin Chemical compound C1CCC(C(=O)NNC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(COC(C)(C)C)NC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 BLCLNMBMMGCOAS-UHFFFAOYSA-N 0.000 description 1
- 230000000955 neuroendocrine Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000003880 polar aprotic solvent Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000541 pulsatile effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 235000020238 sunflower seed Nutrition 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical group 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000010698 whale oil Substances 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Dispersion Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Pulmonology (AREA)
- Pregnancy & Childbirth (AREA)
- Urology & Nephrology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (12)
1. Farmaceutisk sammensætning, der omfatter: a) mindst én sorbitan-umættet fedtsyreester, der har et polært hoved med mindst to eller flere -OH (hydroxyl)-grupper; b) mindst ét phospholipid; c) mindst ét væskeformigt krystalhærdemiddel, som er fri for en ioniserbar gruppe, der har en hydrofob del på 15 til 40 carbonatomer med en triacylgruppe eller en carbonringstruktur; og d) mindst én GnRH (gonadotropinfrigørende hormon)-analog som et farmakologisk aktivt stof, hvor lipidprækoncentratet forefindes som en væskefase i fravær af vandig væske og omdannes til et væskeformigt krystal i nærvær af vandig væske, hvor GnRH-analogen er en GnRH-agonist, der er valgt fra gruppen, der består af leuprolid, goserelin, triptorelin, nafarelin, buserelin, histrelin, deslorelin, meterelin, gonadrelin, et farmaceutisk acceptabelt salt deraf og en kombination deraf, eller hvor GnRH-analogen er en GnRH-antagonist, der er valgt fra gruppen, der består af degarelix, abarelix, ganirelix, cetrorelix, et farmaceutisk acceptabelt salt deraf og en kombination deraf.
2. Farmaceutisk sammensætning ifølge krav 1, hvor sorbitan- umættet fedtsyreesteren er valgt fra gruppen, der består af sorbitanmonooleat, sorbitanmonolinoleat, sorbitanmonopalmitoleat, sorbitanmonomyristoleat, sorbitansesquioleat, sorbitansesquilinoleat, sorbitansesquipalmitoleat, sorbitansesquimyristoleat, sorbitandioleat, sorbitandilinoleat, sorbitandipalmitoleat, sorbitandimyristoleat og en kombination deraf.
3. Farmaceutisk sammensætning ifølge krav 1, hvor sorbitan- umættet fedtsyreesteren er valgt fra gruppen, der består af sorbitanmonooleat, sorbitanmonolinoleat, sorbitanmonopalmitoleat, sorbitanmonomyristoleat, sorbitansesquioleat og en kombination deraf.
4. Farmaceutisk sammensætning ifølge krav 1, hvor phospholipidet indeholder en mættet eller umættet alkylestergruppe med 4 til 30 carbonatomer og er valgt fra gruppen, der består af phosphatidylcholin, phosphatidylethanolamin, phosphatidyIserin, phosphatidylglycerin, phosphatidylinositol, phosphatidsyre, sphingomyelin og en kombination deraf.
5. Farmaceutisk sammensætning ifølge krav 1, hvor det væskeformige krystalhærdemiddel er valgt fra gruppen, der består af triglycerid, retinylpalmitat, tocopherolacetat, cholesterol, benzylbenzoat, ubiquinon og en kombination deraf.
6. Farmaceutisk sammensætning ifølge krav 1, hvor det væskeformige krystalhærdemiddel er valgt fra gruppen, der består af tocopherolacetat, cholesterol og en kombination deraf.
7. Farmaceutisk sammensætning ifølge krav 1 til anvendelse til forebyggelse eller behandling af en kønshormonafhængig sygdom eller som et kontraceptiv.
8. Farmaceutisk sammensætning til anvendelse ifølge krav 7, hvor den kønshormonafhængige sygdom er valgt fra gruppen, der består af prostatacancer, brystcancer, ovariecancer, endometriose, uterusfibrom, polycystisk ovariesygdom, tidlig pubertet, hypertrikose, gonadotrope hypofyseadenomer, søvnapnøsyndrom, irritabel tarmsyndrom, præmenstruelt syndrom, benign prostatahyperplasi og infertilitet.
9. Farmaceutisk sammensætning ifølge krav 1, der omfatter: a) mindst én sorbitan-umættet fedtsyreester, der har et polært hoved med mindst to eller flere -OH (hydroxyl)-grupper, i en mængde på 9~90 vægt-%; b) mindst ét phospholipid i en mængde på 9~90 vægt-%; c) mindst ét væskeformigt krystalhærdemiddel, der er fri for en ioniserbar gruppe og har en triacylgruppe med 15 til 40 carbonatomer eller en carbonringstruktur i en hydrofob del, i en mængde på 0,1-50 vægt-%; og d) mindst én GnRH (gonadotropinfrigørende hormon)-analog i en mængde på 0,01-50 vægt-%.
10. Farmaceutisk sammensætning ifølge krav 1, der omfatter: a) mindst én sorbitan-umættet fedtsyreester, der har et polært hoved med mindst to eller flere -OH (hydroxyl)-grupper, i en mængde på 9-64 vægt-%; b) mindst ét phospholipid i en mængde på 18-76 vægt-%; c) mindst ét væskeformigt krystalhærdemiddel, der er fri for en ioniserbar gruppe og har en triacylgruppe med 15 til 40 carbonatomer eller en carbonringstruktur i en hydrofob del, i en mængde på 1-36 vægt-%; og d) leuprolid eller et farmaceutisk acceptabelt salt deraf i en mængde på 0,1-50 vægt-%.
11. Farmaceutisk sammensætning ifølge krav 1, der omfatter: a) mindst én sorbitan-umættet fedtsyreester, der har et polært hoved med mindst to eller flere -OH (hydroxyl)-grupper, i en mængde på 9-64 vægt-%; b) mindst ét phospholipid i en mængde på 18-76 vægt-%; c) mindst ét væskeformigt krystalhærdemiddel, der er fri for en ioniserbar gruppe og har en triacylgruppe med 15 til 40 carbonatomer eller en carbonringstruktur i en hydrofob del, i en mængde på 1-36 vægt-%; og d) goserelin eller et farmaceutisk acceptabelt salt deraf i en mængde på 0,1-50 vægt-%.
12. Farmaceutisk sammensætning ifølge krav 1, der omfatter: a) mindst én sorbitan-umættet fedtsyreester, der har et polært hoved med mindst to eller flere -OH (hydroxyl)-grupper, i en mængde på 9-64 vægt-%; b) mindst ét phospholipid i en mængde på 18-76 vægt-%; c) mindst ét væskeformigt krystalhærdemiddel, der er fri for en ioniserbar gruppe og har en triacylgruppe med 15 til 40 carbonatomer eller en carbonringstruktur i en hydrofob del, i en mængde på 1-36 vægt-%; og d) degarelix eller et farmaceutisk acceptabelt salt deraf i en mængde på 2~50 vægt-%.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020120157583A KR101586791B1 (ko) | 2012-12-28 | 2012-12-28 | ＧｎＲＨ 유도체의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물 |
| PCT/KR2013/012269 WO2014104791A1 (en) | 2012-12-28 | 2013-12-27 | Sustained-release lipid pre-concentrate of gnrh analogues and pharmaceutical composition comprising the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2938332T3 true DK2938332T3 (da) | 2018-06-06 |
Family
ID=51021736
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK13867921.2T DK2938332T3 (da) | 2012-12-28 | 2013-12-27 | Depot-lipidprækoncentrat af gnrh-analoger og farmaceutisk sammensætning dermed |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US10722585B2 (da) |
| EP (1) | EP2938332B1 (da) |
| JP (1) | JP6078660B2 (da) |
| KR (1) | KR101586791B1 (da) |
| CN (2) | CN105188680A (da) |
| AU (1) | AU2013371101B2 (da) |
| BR (1) | BR112015015518B1 (da) |
| CA (1) | CA2888863C (da) |
| DK (1) | DK2938332T3 (da) |
| ES (1) | ES2664598T3 (da) |
| HU (1) | HUE036932T2 (da) |
| LT (1) | LT2938332T (da) |
| MX (1) | MX364595B (da) |
| NO (1) | NO2938332T3 (da) |
| NZ (1) | NZ710468A (da) |
| PH (1) | PH12015500936B1 (da) |
| PL (1) | PL2938332T3 (da) |
| PT (1) | PT2938332T (da) |
| RU (1) | RU2646487C2 (da) |
| SI (1) | SI2938332T1 (da) |
| TR (1) | TR201806985T4 (da) |
| WO (1) | WO2014104791A1 (da) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101494594B1 (ko) | 2011-08-30 | 2015-02-23 | 주식회사 종근당 | 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물 |
| KR101586789B1 (ko) * | 2012-12-28 | 2016-01-19 | 주식회사 종근당 | 양이온성 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물 |
| ES2642172T3 (es) | 2013-01-31 | 2017-11-15 | Chong Kun Dang Pharmaceutical Corp. | Compuestos derivados de ciclohexeno sustituidos con biarilo o biarilo heterocíclico como inhibidores de CETP |
| KR101601035B1 (ko) | 2013-02-28 | 2016-03-08 | 주식회사 종근당 | 키토산 및 액상결정 형성 물질을 포함하는 유전자 전달용 조성물 |
| US9618507B2 (en) | 2014-02-24 | 2017-04-11 | Betanien Hospital | Methods of treating rheumatoid arthritis |
| KR101809908B1 (ko) | 2014-07-21 | 2018-01-25 | 주식회사 종근당 | 5-알파환원효소억제제를 포함하는 조성물 |
| US10821152B2 (en) | 2014-08-26 | 2020-11-03 | Betanien Hospital | Methods, agents and compositions for treatment of inflammatory conditions |
| CN107257681A (zh) * | 2014-12-23 | 2017-10-17 | 卡姆拉斯公司 | 控释配制品 |
| MX383392B (es) | 2016-09-27 | 2025-03-13 | Camurus Ab | Mezclas y formulaciones que comprenden una sal de alquil amonio de ácido etilendiaminotetraacético (edta). |
| US11376220B2 (en) * | 2017-06-30 | 2022-07-05 | Therio, LLC | Single-injection methods and formulations to induce and control multiple ovarian follicles in bovine, caprine, ovine, camelid and other female animals |
| US10994018B2 (en) * | 2017-09-27 | 2021-05-04 | Novel Pharma Inc. | Long-acting palmitic acid-conjugated GnRH derivative, and pharmaceutical composition containing same |
| WO2020196946A1 (ko) * | 2019-03-26 | 2020-10-01 | 노벨파마 주식회사 | 지속형 지방산 결합 GnRH 유도체 및 이를 포함하는 약제학적 조성물 |
| US20200330547A1 (en) * | 2019-04-22 | 2020-10-22 | Tolmar International Limited | Method of Treating a Child with Central Precocious Puberty using an Extended Release Composition |
| EP4098281A4 (en) * | 2020-01-27 | 2024-03-20 | Farnex Incorporated | HIGH SAFE NONLAMELLAR LIQUID CRYSTAL FORMING COMPOSITION |
| KR102628523B1 (ko) * | 2020-06-30 | 2024-01-24 | 주식회사 종근당 | GnRH 유도체를 포함하는 주사용 조성물 |
| CN113368041B (zh) * | 2020-07-17 | 2023-01-03 | 丽珠医药集团股份有限公司 | 药物组合物、缓释制剂及其制备方法 |
| WO2022215899A1 (ko) * | 2021-04-08 | 2022-10-13 | 주식회사 티온랩테라퓨틱스 | 서방성 지질 전구 제제 |
| KR20230124229A (ko) * | 2022-02-18 | 2023-08-25 | (주)인벤티지랩 | 데슬로렐린을 포함하는 서방성 주사용 조성물 |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3684887D1 (de) | 1985-11-29 | 1992-05-21 | Biomatrix Inc | Arzneistoffabgabesysteme auf basis von hyaluronan, dessen derivaten und salzen sowie verfahren zu deren herstellung. |
| DE3706036A1 (de) | 1987-02-25 | 1988-09-08 | Basf Ag | Polyacetale, verfahren zu deren herstellung aus dialdehyden und polyolcarbonsaeuren und verwendung der polyacetale |
| MY107937A (en) | 1990-02-13 | 1996-06-29 | Takeda Chemical Industries Ltd | Prolonged release microcapsules. |
| US5211952A (en) * | 1991-04-12 | 1993-05-18 | University Of Southern California | Contraceptive methods and formulations for use therein |
| GB9302492D0 (en) | 1993-02-09 | 1993-03-24 | Procter & Gamble | Cosmetic compositions |
| FR2709666B1 (fr) | 1993-09-07 | 1995-10-13 | Oreal | Composition cosmétique ou dermatologique constituée d'une émulsion huile dans eau à base de globules huileux pourvus d'un enrobage cristal liquide lamellaire. |
| SE518578C2 (sv) * | 1994-06-15 | 2002-10-29 | Gs Dev Ab | Lipidbaserad komposition |
| EP0711557A1 (de) | 1994-11-09 | 1996-05-15 | Ciba-Geigy Ag | Pharmazeutische Formulierungsgrundlage |
| WO1996032930A1 (en) | 1995-04-18 | 1996-10-24 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Liposome drug-loading method and composition |
| EP0760237A1 (en) | 1995-08-30 | 1997-03-05 | Cipla Limited | Oil-in-water microemulsions |
| US5736152A (en) | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
| US5968895A (en) * | 1996-12-11 | 1999-10-19 | Praecis Pharmaceuticals, Inc. | Pharmaceutical formulations for sustained drug delivery |
| AU6919598A (en) * | 1997-04-17 | 1998-11-13 | Dumex-Alpharma A/S | A novel bioadhesive drug delivery system based on liquid crystals |
| PT942780E (pt) | 1997-09-09 | 2003-11-28 | Lyotropic Therapeutics Inc | Particulas revestidas processos de obtencao e uso |
| US6919372B1 (en) | 1997-12-26 | 2005-07-19 | Yamanouchi Pharmaceutical Co., Ltd. | Sustained release pharmaceutical compositions |
| TWI241915B (en) | 1998-05-11 | 2005-10-21 | Ciba Sc Holding Ag | A method of preparing a pharmaceutical end formulation using a nanodispersion |
| US6565874B1 (en) | 1998-10-28 | 2003-05-20 | Atrix Laboratories | Polymeric delivery formulations of leuprolide with improved efficacy |
| ATE404172T1 (de) * | 1998-12-30 | 2008-08-15 | Dexcel Ltd | Dispergierbares konzentrat zur verabreichung von cyclosporin |
| US7374779B2 (en) | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
| IE990935A1 (en) | 1999-11-08 | 2002-04-03 | Procter & Gamble | Cosmetic Compositions |
| AU781682B2 (en) | 2000-03-20 | 2005-06-09 | Zoetis Services Llc | Sustained-release compositions for parenteral administration |
| US20030070679A1 (en) | 2001-06-01 | 2003-04-17 | Boehringer Ingelheim Pharma Kg | Capsules containing inhalable tiotropium |
| AU2002334358B2 (en) | 2001-09-06 | 2008-02-07 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | A method for preparing liposome formulations with a predefined release profile |
| US7731947B2 (en) | 2003-11-17 | 2010-06-08 | Intarcia Therapeutics, Inc. | Composition and dosage form comprising an interferon particle formulation and suspending vehicle |
| US7713440B2 (en) * | 2003-10-08 | 2010-05-11 | Lyotropic Therapeutics, Inc. | Stabilized uncoated particles of reversed liquid crystalline phase materials |
| PL1682091T3 (pl) | 2003-11-07 | 2017-09-29 | Camurus Ab | Kompozycje lipidów i kationowych peptydów |
| WO2006075124A1 (en) | 2005-01-14 | 2006-07-20 | Camurus Ab | Somatostatin analogue formulations |
| US20050118206A1 (en) * | 2003-11-14 | 2005-06-02 | Luk Andrew S. | Surfactant-based gel as an injectable, sustained drug delivery vehicle |
| TW200529890A (en) | 2004-02-10 | 2005-09-16 | Takeda Pharmaceutical | Sustained-release preparations |
| US8236292B2 (en) * | 2004-06-04 | 2012-08-07 | Camurus Ab | Liquid depot formulations |
| PL1848403T3 (pl) | 2005-01-14 | 2010-09-30 | Camurus Ab | Preparaty bioadhezyjne o działaniu miejscowym |
| US9757461B2 (en) | 2005-01-14 | 2017-09-12 | Camurus Ab | GnRH analogue formulations |
| KR101245022B1 (ko) * | 2005-01-21 | 2013-03-19 | 카무러스 에이비 | 약제학적 지질 조성물 |
| GB0501364D0 (en) * | 2005-01-21 | 2005-03-02 | Camurus Ab | Compositions |
| US20060182790A1 (en) | 2005-02-17 | 2006-08-17 | Flor Mayoral | Dermal medicaments application enhancer |
| EP1712220A1 (en) | 2005-04-15 | 2006-10-18 | PARI GmbH Spezialisten für effektive Inhalation | Pharmaceutical aerosol composition |
| US20080102128A1 (en) | 2006-07-28 | 2008-05-01 | Flamel Technologies, Inc. | Modified-release microparticles based on amphiphilic copolymer and on active principles(s) and pharmaceutical formulations comprising them |
| US9918934B2 (en) | 2006-12-12 | 2018-03-20 | Edgar Joel Acosta-Zara | Linker-based lecithin microemulsion delivery vehicles |
| GB0711656D0 (en) | 2007-06-15 | 2007-07-25 | Camurus Ab | Formulations |
| GB0716385D0 (en) | 2007-08-22 | 2007-10-03 | Camurus Ab | Formulations |
| EP2244679A4 (en) | 2008-02-08 | 2013-10-09 | Qps Llc | NON-POLYMERIC COMPOSITIONS FOR CONTROLLED MEDICINAL PRODUCTION |
| WO2009114959A1 (zh) | 2008-03-20 | 2009-09-24 | 中国人民解放军军事医学科学院毒物药物研究所 | 可注射用缓释药物制剂及其制备方法 |
| JP5685193B2 (ja) | 2008-11-19 | 2015-03-18 | メリアル リミテッド | セフチオフルおよびケトプロフェンとまたはセフチオフルとベンジルアルコールとを含む製剤 |
| EP2544662B1 (en) | 2010-03-10 | 2020-05-20 | Nuvo Pharmaceuticals Inc. | Foamable formulation |
| KR20120093677A (ko) | 2011-02-15 | 2012-08-23 | 삼성전자주식회사 | 엑스레이 촬영시스템 및 엑스레이 촬영시스템의 위치보정 방법 |
| KR101319420B1 (ko) | 2011-03-18 | 2013-10-17 | 한남대학교 산학협력단 | 서방형 방출이 가능한 수용성 양이온 약물 전달 시스템 |
| WO2012165468A1 (ja) * | 2011-05-31 | 2012-12-06 | 学校法人 聖マリアンナ医科大学 | 親油性化合物を高濃度で含有する液晶組成物の製造方法及びその方法によって製造された液晶組成物 |
| KR101494594B1 (ko) | 2011-08-30 | 2015-02-23 | 주식회사 종근당 | 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물 |
| KR101383324B1 (ko) | 2011-11-10 | 2014-04-28 | 주식회사 종근당 | 신규한 유전자 전달용 조성물 |
| KR101586790B1 (ko) | 2012-12-28 | 2016-01-19 | 주식회사 종근당 | 음이온성 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물 |
| KR101586789B1 (ko) | 2012-12-28 | 2016-01-19 | 주식회사 종근당 | 양이온성 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물 |
| ES2642172T3 (es) | 2013-01-31 | 2017-11-15 | Chong Kun Dang Pharmaceutical Corp. | Compuestos derivados de ciclohexeno sustituidos con biarilo o biarilo heterocíclico como inhibidores de CETP |
| KR101601035B1 (ko) | 2013-02-28 | 2016-03-08 | 주식회사 종근당 | 키토산 및 액상결정 형성 물질을 포함하는 유전자 전달용 조성물 |
-
2012
- 2012-12-28 KR KR1020120157583A patent/KR101586791B1/ko active Active
-
2013
- 2013-12-27 PL PL13867921T patent/PL2938332T3/pl unknown
- 2013-12-27 PT PT138679212T patent/PT2938332T/pt unknown
- 2013-12-27 CN CN201380067822.5A patent/CN105188680A/zh active Pending
- 2013-12-27 CN CN202110625866.1A patent/CN113350480A/zh active Pending
- 2013-12-27 NO NO13867921A patent/NO2938332T3/no unknown
- 2013-12-27 HU HUE13867921A patent/HUE036932T2/hu unknown
- 2013-12-27 JP JP2015550323A patent/JP6078660B2/ja active Active
- 2013-12-27 SI SI201331022T patent/SI2938332T1/sl unknown
- 2013-12-27 CA CA2888863A patent/CA2888863C/en active Active
- 2013-12-27 MX MX2015008401A patent/MX364595B/es active IP Right Grant
- 2013-12-27 DK DK13867921.2T patent/DK2938332T3/da active
- 2013-12-27 AU AU2013371101A patent/AU2013371101B2/en active Active
- 2013-12-27 WO PCT/KR2013/012269 patent/WO2014104791A1/en not_active Ceased
- 2013-12-27 TR TR2018/06985T patent/TR201806985T4/tr unknown
- 2013-12-27 RU RU2015131107A patent/RU2646487C2/ru active
- 2013-12-27 EP EP13867921.2A patent/EP2938332B1/en active Active
- 2013-12-27 LT LTEP13867921.2T patent/LT2938332T/lt unknown
- 2013-12-27 ES ES13867921.2T patent/ES2664598T3/es active Active
- 2013-12-27 BR BR112015015518-9A patent/BR112015015518B1/pt active IP Right Grant
- 2013-12-27 US US14/440,060 patent/US10722585B2/en active Active
- 2013-12-27 NZ NZ710468A patent/NZ710468A/en unknown
-
2015
- 2015-04-27 PH PH12015500936A patent/PH12015500936B1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| LT2938332T (lt) | 2018-05-25 |
| JP2016504353A (ja) | 2016-02-12 |
| EP2938332A4 (en) | 2016-08-17 |
| BR112015015518B1 (pt) | 2022-08-23 |
| MX2015008401A (es) | 2016-02-16 |
| EP2938332B1 (en) | 2018-02-21 |
| MX364595B (es) | 2019-05-02 |
| KR101586791B1 (ko) | 2016-01-19 |
| KR20140086741A (ko) | 2014-07-08 |
| CN105188680A (zh) | 2015-12-23 |
| BR112015015518A2 (pt) | 2017-07-11 |
| PH12015500936A1 (en) | 2015-07-06 |
| ES2664598T3 (es) | 2018-04-20 |
| HUE036932T2 (hu) | 2018-08-28 |
| PH12015500936B1 (en) | 2019-01-30 |
| RU2646487C2 (ru) | 2018-03-05 |
| JP6078660B2 (ja) | 2017-02-08 |
| SI2938332T1 (sl) | 2018-10-30 |
| CA2888863A1 (en) | 2014-07-03 |
| RU2015131107A (ru) | 2017-02-01 |
| PL2938332T3 (pl) | 2018-08-31 |
| NZ710468A (en) | 2016-04-29 |
| WO2014104791A1 (en) | 2014-07-03 |
| AU2013371101A1 (en) | 2015-08-13 |
| CN113350480A (zh) | 2021-09-07 |
| TR201806985T4 (tr) | 2018-06-21 |
| AU2013371101B2 (en) | 2017-01-05 |
| NO2938332T3 (da) | 2018-07-21 |
| CA2888863C (en) | 2018-04-03 |
| US10722585B2 (en) | 2020-07-28 |
| EP2938332A1 (en) | 2015-11-04 |
| PT2938332T (pt) | 2018-04-06 |
| US20150297726A1 (en) | 2015-10-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2938332T3 (da) | Depot-lipidprækoncentrat af gnrh-analoger og farmaceutisk sammensætning dermed | |
| AU2013371094B2 (en) | Sustained-release lipid pre-concentrate of cationic pharmacologically active substance and pharmaceutical composition comprising the same | |
| DK2750667T3 (da) | Depotlipidprækoncentrat af farmakologisk aktivt stof og farmaceutisk sammensætning, der omfatter dette | |
| JP5671451B2 (ja) | ＧｎＲＨ関連化合物の組成物および調製プロセス | |
| ES2458992T3 (es) | Formulaciones de análogos de GnRH | |
| CA3038412A1 (en) | Mixtures and formulations comprising an alkyl ammonium edta salt | |
| KR102628523B1 (ko) | GnRH 유도체를 포함하는 주사용 조성물 | |
| RU2827376C1 (ru) | ИНЪЕКЦИОННАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ АНАЛОГ GnRH |